FDA approves inavolisib with palbociclib and fulvestrant for ...
WEB3 days ago · News and Events; Training and Continuing Education ... HER2-negative locally advanced or metastatic breast cancer whose disease progressed during or within 12 months of completing adjuvant ...
Breast cancer deaths in the US continue to fall, but new ...
WEBOct 1, 2024 · The study, published Tuesday in CA: A Cancer Journal for Clinicians, found some good news: The overall breast cancer death rate in the US dropped about 44% between 1989 and 2022, which translates ...
FDA approves Roche’s Itovebi, a targeted treatment for ...
WEB1 day ago · HR-positive breast cancer is the most prevalent type of all breast cancers, accounting for approximately 70% of cases. 4,5 A defining feature of HR-positive breast cancer is that its tumour cells ...
Breast cancer treatment: Drug Kisqali approval expanded for ...
WEBSep 17, 2024 · The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to treat patients with earlier stage cancer, Novartis said. The drug was found to reduce the risk of a patient's...
New study finds triple-negative breast cancer tumors with an ...
WEBApr 25, 2024 · A new multicenter, international study suggests that people who have early-stage triple-negative breast cancer (TNBC) and high levels of immune cells within their tumors may have a lower risk of recurrence and better survival rates even when not treated with chemotherapy.
Breast Cancer News - ScienceDaily
WEB6 days ago · Breast cancer research including information on breast cancer symptoms, prevention strategies, screening techniques, and new breast cancer treatments.
Estrogen a more powerful breast cancer culprit than we realized
WEBMay 17, 2023 · A Harvard Medical School study shows the sex hormone estrogen — thus far thought to be only a fuel for breast cancer growth — can directly cause tumor-driving genomic rearrangements.
Breast Cancer Drug Trial Results in ‘Unheard-Of’ Survival
WEBJun 7, 2022 · The clinical trial, sponsored by the pharmaceutical companies Daiichi Sankyo and AstraZeneca and led by Dr. Shanu Modi of Memorial Sloan Kettering Cancer Center, involved 557 patients with...
Targeting HER2-positive breast cancer: advances and future ...
WEBNov 7, 2022 · The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading...
Experimental immunotherapy targets metastatic breast cancer
WEBFeb 1, 2022 · Many people with metastatic breast cancer can mount an immune reaction against their tumors, the study found, a prerequisite for this type of immunotherapy, which relies on what are called tumor-infiltrating lymphocytes (TILs).